James Pickens Jr., Family History, and Prostate Cancer

What James Pickens Jr. disclosed

In November 2025, the "Grey's Anatomy" actor James Pickens Jr., then 71, posted an Instagram video saying he is "living proof" that early detection for prostate cancer "works." CNN reported the disclosure.

Speaking with Black Health Matters, Pickens said he has always kept up his yearly physical, and that prostate cancer runs in his family. His doctor checked his PSA in 2024, and when the number ticked up again at a repeat test in January, his primary physician sent him back to a urologist. An MRI showed something suspicious, and a biopsy found a tumor. A PET scan showed the cancer had not spread and that it sat in one part of the gland. He then chose a radical prostatectomy — removal of the whole prostate — carried out robotically.

He described the reaction of his medical team this way: "It was rare enough that they wanted to make sure that they were crossing all the T's and dotting all their I's. But they hadn't seen one that was detected as early as mine."

In his video, he noted that risk is higher in Black men, and added that "early detection is key."

That is what he chose to share. The rest of this article is about the pathway he described, because most people never learn what an abnormal blood test actually sets in motion.

Step one: a number, not a diagnosis

The blood test in question measures prostate-specific antigen, or PSA, a protein made by the prostate gland.

The National Cancer Institute is careful about what a raised PSA means. Levels can be high in men who have prostate cancer. They can also be high with an infection, with inflammation of the prostate, or with benign prostatic hyperplasia, a non-cancerous enlargement common with age.

So an elevated PSA is a question. It is not an answer, and it does not on its own mean cancer.

Step two: imaging and tissue

NCI lists the tests that follow. A digital rectal exam lets a clinician feel the prostate through the rectal wall for lumps or hard areas. A PSMA PET scan is a newer imaging test used in prostate cancer.

Then the biopsy. Small tissue samples are taken from the prostate and examined under a microscope. Only that step can confirm cancer, and it also produces the grade.

NCI describes the grading system. Pathologists score tissue patterns from 1, well differentiated and closest to normal, to 5, very poorly differentiated. The two most common patterns are added to give a Gleason score from 2 to 10. It is usually written out as its parts, so a 3 + 4 = 7 is a different tumor from a 4 + 3 = 7, because in the second the more aggressive pattern dominates.

More than 95% of primary prostate cancers are adenocarcinomas, meaning they arise from gland cells. NCI notes these tumors are often multifocal, appearing in more than one spot in the same gland.

Why family history and race change the math

Pickens mentioned both a family history and higher risk in Black men. Both are documented.

NCI's screening guidance for clinicians gives the mortality figures directly. For 2022, age-adjusted prostate cancer death rates per 100,000 were 18.7 overall, 17.9 for White men, and 36.4 for Black men. That is roughly double.

The same guidance places prostate cancer in context. It is the most common cancer diagnosed in North American men, excluding skin cancers, and the second-leading cause of cancer death in men after lung cancer. It accounts for 30% of all cancers in males and 11% of cancer deaths.

There is also good news in the trend. NCI reports that between 1993 and 2022, prostate cancer mortality rates declined by about 50%.

When to get checked

Prostate cancer often causes nothing at all until it is advanced. NCI lists these urinary signs to raise with a doctor:

• Trouble starting the flow of urine.
• Frequent urination, especially at night.
• Trouble emptying the bladder completely.
• A weak or interrupted, stop-and-go stream.

For advanced disease, NCI adds pain in the back, hips, or pelvis that will not go away, plus signs of anemia such as breathlessness, unusual tiredness, fast heartbeat, dizziness, or pale skin.

Practical thresholds worth carrying:

• A first conversation about PSA testing belongs somewhere around age 45 to 50 for most men, and earlier if a father or brother had prostate cancer, or if you are Black. Bring it up yourself; do not wait to be asked.
• New urinary symptoms after 50 deserve an appointment, even if the likeliest answer is benign enlargement.
• Blood in the urine or semen always needs evaluation.
• Persistent bone pain in the back, hips, or pelvis in a man with a prostate cancer history should be reported quickly, not at the next routine visit.

The trade-off nobody should skip

Testing has real costs, and an honest article says so.

The U.S. Preventive Services Task Force, in its recommendation of May 8, 2018, made PSA screening a grade C decision for men aged 55 to 69, meaning an individual choice made after discussing benefits and harms with a clinician. For men 70 and older it is a grade D, a recommendation against.

USPSTF lists the harms: false-positive results that require more testing and possibly a biopsy, overdiagnosis and overtreatment, and treatment complications such as incontinence and erectile dysfunction.

NCI adds the reason overdiagnosis is such a problem here. Clinically indolent tumors, meaning tumors that would never have caused harm, are estimated at 30% to 70% in men older than 60, based on autopsy studies of men who died of other causes.

That is why active surveillance is a genuine option for low-risk disease. It means regular PSA tests, examinations, imaging, and repeat biopsies, with treatment held back unless the cancer starts to move.

What the population numbers show

These describe groups, not any individual.

SEER, NCI's cancer surveillance program, reports the American Cancer Society's projection of 333,830 new prostate cancers in the United States in 2026 and 36,320 deaths. About 13.2% of men will be diagnosed with prostate cancer at some point in their lives. In 2023 an estimated 3,700,086 men in the United States were living with the disease.

Five-year relative survival across all stages is 98.2% for men diagnosed from 2016 to 2022. By stage, SEER records 100.0% for localized disease, 100.0% for regional disease, and 40.1% for distant disease. About 69% of cases are found while localized, and 9% are already distant.

That gap between 100.0% and 40.1% is what the phrase "early detection" is pointing at. It is a statement about a large population, not a promise to a particular man, and it is exactly why the decision to test is worth a real conversation.

Sources

• NCI: Prostate Cancer Screening (PDQ) — Health Professional Version
• NCI: Prostate Cancer Treatment (PDQ) — Health Professional Version
• NCI: Prostate Cancer Treatment (PDQ) — Patient Version
• SEER Cancer Stat Facts: Prostate Cancer
• USPSTF: Prostate Cancer Screening, final recommendation, May 8, 2018
• CNN: 'Grey's Anatomy' star James Pickens Jr. opens up about his prostate cancer diagnosis, touts early detection